Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Biofil Chemicals & Pharmaceuticals Limited

NSE: BIOFILCHEMPharmaceuticals

Share price

₹30.15

+2.13% close of 9 Oct 2026

Market cap ₹49 CrP/E 102.2

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

52

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹49 Cr

P/E ratio

102.2

P/B ratio

2.3

ROCE

3.0%

ROE

13.8%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹46.3452-week low ₹25.79

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Our sales figures for this company step up at Sep 2023 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.

Whether it grew faster than its sector

Our sales figures for this company step up at Sep 2023 and we hold nothing that says why, so there is no honest growth rate of its own to set against its sector.

Room to re-rate, or risk of de-rating

At 102.2× earnings it costs 4.2× the market, which pays 24.1× across 2199 companies we can price. Its own industry sits at 47.4×, across 4 companies. It is against its own five-year median of 135.0×, the 22nd percentile of its own range.

Whether growth justifies the valuation

Priced at 1.4 times its growth rate, on earnings growth of 71%.

Profit growthPrice per ₹1 profitPer 1% growth
Biofil Chemicals & Pharmaceuticals Limited — this one71%/yr102.2×₹1.4
Gujarat Themis Biosyn Limited-7%/yr97.0×—
Zota Health Care LImited———
RPG Life Sciences Limited—37.8×—
SMS Pharmaceuticals Limited155%/yr39.1×—
Gufic Biosciences Limited—55.7×—

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 111 of 130 on returns, 15 of 127 on growth, 117 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 3.0% on capital, ahead of 15% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years the business itself consumed ₹0 crore of cash before any plant spend, funded mostly borrowed — borrowings rose from ₹0 crore to ₹3 crore. But only about 35 of every 100 rupees of profit it reported over 12 years arrived as cash — the rest is tied up. Its cash comes back more slowly than it used to: it went from being waiting 125.3 days for its cash to waiting 152.2 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 10 checks clear · 80%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 11 Aug 2026 · Standalone · Unaudited

Revenue

₹12 Cr

Revenue vs last year

+92.1%

Revenue vs last quarter

+63.1%

Net profit

₹0 Cr

Profit vs last year

-95.5%

Profit vs last quarter

-48.0%

Net margin

0.9%

EPS

₹0.07

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹49 Cr
Prev close
₹30.15
52w High
₹46.3
52w Low
₹25.6
Enterprise value
₹49 Cr
Beta
1.1
Price CAGR 1y
-25.0%
Price CAGR 3y
-17.0%
Price CAGR 5y
-15.0%
Price CAGR 10y
15.0%

Ratios

Return on assets
6.5%
PEG ratio
1.5
P/E ratio
102.2
P/B ratio
2.3
EV / EBITDA
62.5
Industry P/E
37.6
ROCE
3.0%
ROCE 5y average
4.6%
ROE
13.8%
Debt / Equity
0.1
Interest coverage
346.0
Dividend yield
0.0%
ROE 3y average
1.0%
ROE last year
-3.0%

Annual P&L

Annual revenue
₹28 Cr
Annual profit
₹3 Cr
Operating margin
2.3%
Net profit margin
9.8%
EBITDA margin
2.3%
Sales growth 3y
-1.9%
Sales growth 5y
-4.5%
Profit growth 3y
71.0%
Profit growth 5y
18.0%
EPS
₹1.7
Sales growth TTM
9.0%
Profit growth TTM
-83.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹12 Cr
Profit latest quarter
₹0 Cr
YoY quarterly sales growth
92.1%
YoY quarterly profit growth
-95.4%
OPM latest quarter
1.1%

Balance Sheet

Book Value
₹13.3
Face Value
₹10.0
Total debt
₹3 Cr
Total cash
₹3 Cr
Borrowings
₹3 Cr
Reserves / Equity
0.3

Cash Flow

Operating cash flow
-₹1 Cr
Free cash flow
₹1 Cr
FCF yield
1.1%
Net cash flow
₹3 Cr

Shareholding

Promoter holding
46.8%
FII holding
0.0%
DII holding
0.1%
Public holding
53.1%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.94,28,0570.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.52,54,6650.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.31,79,1640.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,14,9630.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.31,10,6990.10362.1125.52,026.329.117.8
Cipla1,327.2029.91,06,9970.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.71,03,8760.04574.129.64,030.612.913.5
Biofil Chemicals30.43102.2490.000.1-95.412.492.13.0
Median417.9034.42,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Standalone · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales2.43175.03158.442.41148.356.43140.867.5712
Expenses2.01174.84158.132.29148.246.42130.777.1412
Material Cost2.081.171.183.231.809.48
Change in Inventories0.32-4.984.84-2.882.83-0.81
Purchases of Stock-in-Trade5.269.747.0701.953.12
Employee Cost0.250.210.180.190.220.19
Other Expenses0.340.280.150.220.330.23
Operating Profit0.420.240.19-0.040.310.120.310.110.010.120.090.430.14
OPM %171.383.78-0.263.674.982.181.320.160.89105.681.13
Other Income0.020.030.030.410.030.020.020.242.830.060.080.110.06
Exceptional items (within Other Income)000000
Interest0.010.0100.020.010.010.010.010.010000
Depreciation0.110.110.110.080.100.100.100.080.070.070.070.070.07
Profit before tax0.320.150.110.270.230.030.220.262.760.110.100.470.13
Tax %25201811263327231327305523
Net Profit0.240.120.090.250.170.020.160.202.410.080.080.210.11
EPS in Rs0.150.070.060.150.100.010.100.121.480.050.050.130.07
Diluted EPS in Rs0.121.480.050.050.130.07

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Standalone · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales5.86131312233036223040332834
Expenses5.12121111222834212939332834
Material Cost5.317.38
Change in Inventories-0.79-0.19
Purchases of Stock-in-Trade2619
Employee Cost0.790.80
Other Expenses0.920.99
Operating Profit0.740.872.610.931.021.821.601.331.160.810.850.650.78
OPM %136.61197.524.416.134.485.943.862.022.542.292.27
Other Income0.460.530.140.100.100.170.800.150.100.490.313.080.31
Exceptional items (within Other Income)00
Interest0.210.150.160.150.160.120.070.040.040.040.040.010
Depreciation0.250.260.280.300.370.410.410.430.430.400.380.270.28
Profit before tax0.740.992.310.580.591.461.921.010.790.860.743.450.81
Tax %202023212018353229172419
Net Profit0.590.781.790.470.481.211.240.700.560.710.562.790.48
EPS in Rs0.360.481.100.290.290.740.760.430.340.440.341.710.30
Diluted EPS in Rs0.341.71
Dividend Payout %000000000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
8%
5 years
-4%
3 years
-2%
TTM
9%

Compounded profit growth

10 years
14%
5 years
18%
3 years
71%
TTM
-83%

Stock price CAGR

10 years
15%
5 years
-15%
3 years
-17%
1 year
-25%

Return on equity

10 years
5%
5 years
2%
3 years
1%
Last year
-3%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161616161616161616161616
Reserves-7.86-5.37-3.58-3.11-2.62-1.39-0.140.561.031.932.515.29
Borrowings2.981.371.431.561.641.190.430.460.520.440.473.02
Other Liabilities2.36127.729.448.9326171.4414283218
Total Liabilities142422242442331931475143
Fixed Assets9.068.989.169.2510109.789.4298.628.346.94
CWIP000000000000
Investments000000000000
Other Assets4.691513151432239.3122384336
Total Assets142422242442331931475143

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity0.010.140.710.461.260.891.11-0.22-0.112.39-1.92-0.60
Cash from Investing Activity-0.17-0.19-0.48-0.38-1.41-0.21-0.10-0.07-0.01-0.02-0.101.14
Cash from Financing Activity0.110.10-0.11-0.02-0.08-0.57-0.83-0.010.02-0.1202.54
Net Cash Flow-0.050.050.130.06-0.240.120.18-0.30-0.112.25-2.033.07
Free Cash Flow-0.16-0.050.230.08-0.150.681.01-0.29-0.122.37-2.020.54

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Standalone
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days227387311383190365176117249301419355
Inventory Days163.467.29382224492416254056
Days Payable19840130534115737417811168268367240
Cash Conversion Cycle45-101480551646130975892171
Working Capital Days-48498810551566412510469114152
ROCE %8.599.64195.06510126.204.734.944.122.97

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Standalone · to 30 Sep 2026
Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters474747474747474747474747
FIIs00.030000000000
DIIs0.080.080.080.080.080.080.080.080.080.080.080.08
Public535353535353535353535353
No. of Shareholders25,86426,58125,48026,42226,11425,91425,68525,19624,82525,35624,99924,660

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -26.8% (₹41.19 → ₹30.15)Brick size ₹1.55 (fixed)Bricks 41
₹40.00₹30.15Nov '25Jan '26Mar '26May '26Aug '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹30.15 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-0.31inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Biofil Chemicals & Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Iron waste (scrap iron for ferrous sulphate manufacture)
  • Sulphuric acid
  • Traded pharmaceutical and chemical products (purchase of goods traded)

Makes products for

  • Cyano Pharma Private Limited

Depends on the price of

  • sulphuric_acid

Sells to

  • Cyano Pharma Private Limited · Dried Ferrous Sulphate (crystal, exsiccated, granular), Microcrystalline Cellulose Powder,…

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE829A01014

Business segments

  • Pharma Division · 67%
  • Chemical Division · 33%

Plants

  • Biofil Chemicals & Pharmaceuticals plant, Plot No. 8, Sector 3, Kheda Industrial Estate, Pithampur

News impact

Big market events that reach Biofil Chemicals & Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Splits, bonuses & buybacks

  • daily-prices repair: 11 rows from NSE's archive (replace 5, delete 0, insert 6), 2018-12-21..2026-02-01 (docs/flat_day_repair.md)1× · 21 Dec 2018

Bulk & block deals

DateWhoBought / soldSharesPrice
27 Aug 2026ORION STOCKS LTDSELL89,848₹32.93
27 Aug 2026ORION STOCKS LTDBUY3,856₹32.94
26 Aug 2026ORION STOCKS LTDSELL2,10,940₹32.63
26 Aug 2026IRAGE BROKING SERVICES LLPBUY1,53,082₹32.76
26 Aug 2026ORION STOCKS LTDBUY61,787₹32.46
26 Aug 2026IRAGE BROKING SERVICES LLPSELL19,542₹32.64
25 Aug 2026ORION STOCKS LTDSELL2,83,492₹33.00
25 Aug 2026IRAGE BROKING SERVICES LLPBUY2,47,278₹32.97
25 Aug 2026ORION STOCKS LTDBUY59,108₹32.69
25 Aug 2026IRAGE BROKING SERVICES LLPSELL45,356₹32.88

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.